STAT

This mental health advocate wants to make addiction and behavioral health a 2020 election issue

Congress may have passed an addiction treatment bill in 2018, but that’s no excuse for lawmakers to get complacent, says @NationalCouncil’s CEO, Chuck Ingoglia.
The CEO of a methadone clinic holds a 35 mg liquid dose of methadone in Rossville, Ga.

WASHINGTON — A top mental health and addiction treatment advocate here wants behavioral health on the ballot in 2020.

It’s a winning issue, according to Chuck Ingoglia, the president and CEO of the National Council for Behavioral Health, a D.C. nonprofit that represents thousands of community mental health providers. According to a presidential primary poll the organization released last month, large majorities of New Hampshire voters believe the federal government isn’t doing enough to address the nation’s addiction and mental health challenges.

After Congress passed a sweeping addiction treatment package in 2018, lawmakers have largely turned their focus to other health care issues, like high prescription drug prices and “surprise” medical bills. But Americans still need more, Ingoglia said in an interview this month. He spoke with STAT

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Approval For Sarepta Drug, MSF Closing Access Campaign And More
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:
STAT2 min read
STAT+: Pharmalittle: We’re Reading About EMA Plans For GLP-1 Shortages, Walgreens Store Closings, And More
The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs.

Related Books & Audiobooks